GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Cyclically Adjusted PS Ratio

AEterna Zentaris (AEterna Zentaris) Cyclically Adjusted PS Ratio : 0.20 (As of Jun. 19, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted PS Ratio?

As of today (2024-06-19), AEterna Zentaris's current share price is $6.0599. AEterna Zentaris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $29.78. AEterna Zentaris's Cyclically Adjusted PS Ratio for today is 0.20.

The historical rank and industry rank for AEterna Zentaris's Cyclically Adjusted PS Ratio or its related term are showing as below:

AEZS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.03   Max: 0.62
Current: 0.25

During the past years, AEterna Zentaris's highest Cyclically Adjusted PS Ratio was 0.62. The lowest was 0.01. And the median was 0.03.

AEZS's Cyclically Adjusted PS Ratio is ranked better than
93.66% of 505 companies
in the Biotechnology industry
Industry Median: 5.29 vs AEZS: 0.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AEterna Zentaris's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $29.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted PS Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.05 0.10 0.05 0.26

AEterna Zentaris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.32 0.32 0.26 0.29

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted PS Ratio falls into.



AEterna Zentaris Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AEterna Zentaris's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6.0599/29.78
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEterna Zentaris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AEterna Zentaris's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.003/126.2576*126.2576
=0.003

Current CPI (Mar. 2024) = 126.2576.

AEterna Zentaris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 1.571 98.367 2.016
201503 10.429 99.789 13.195
201506 17.909 100.500 22.499
201509 7.522 100.421 9.457
201512 1.030 99.947 1.301
201603 2.444 101.054 3.054
201606 0.970 102.002 1.201
201609 2.690 101.765 3.337
201612 2.621 101.449 3.262
201703 1.977 102.634 2.432
201706 1.723 103.029 2.111
201709 1.525 103.345 1.863
201712 1.079 103.345 1.318
201803 149.442 105.004 179.690
201806 1.024 105.557 1.225
201809 4.043 105.636 4.832
201812 7.648 105.399 9.162
201903 0.226 106.979 0.267
201906 1.121 107.690 1.314
201909 1.675 107.611 1.965
201912 0.090 107.769 0.105
202003 4.977 107.927 5.822
202006 0.289 108.401 0.337
202009 0.228 108.164 0.266
202012 3.774 108.559 4.389
202103 1.748 110.298 2.001
202106 1.307 111.720 1.477
202109 0.867 112.905 0.970
202112 0.833 113.774 0.924
202203 1.250 117.646 1.342
202206 -0.183 120.806 -0.191
202209 1.532 120.648 1.603
202212 2.044 120.964 2.133
202303 1.753 122.702 1.804
202306 1.850 124.203 1.881
202309 0.002 125.230 0.002
202312 0.100 125.072 0.101
202403 0.003 126.258 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (NAS:AEZS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AEterna Zentaris Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.